TAS 102

Phase 3Small molecule

Taiho Oncology, Inc.

TAS 102 is one of 119 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerCompleted

RadiotherapyNot yet recruiting

Gastric AdenocarcinomaActive, not recruiting

Advanced or Metastatic Solid TumorRecruiting

Colon AdenocarcinomaRecruiting

McrcActive, not recruiting

Colorectal CancerPhase 3

Completed

RadiotherapyPhase 2

Not yet recruiting

Gastric AdenocarcinomaPreclinical

Active, not recruiting

Advanced or Metastatic Solid TumorPhase 1

Recruiting

Colon AdenocarcinomaPhase 1

Recruiting

McrcPhase 1

Active, not recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

34 2

Keytruda

Merck & Co.

Phase 3

25 3

Opdivo

Bristol-Myers Squibb

Phase 3

24 4

Tecentriq

Roche

Phase 3

6 5

Decadron

AAspen Global Incorporated

Phase 3

7 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 7

TAS 102

Taiho Oncology, Inc.

Phase 3

8 8

Cytokine-Induced Killer Cells

TThe First People's Hospital of Changzhou

Phase 3

2 9

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 10

Iron Isomaltoside

TThomas Jefferson University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Gastric Cancer

NCT06346392

Phase 1Recruiting

Colon Adenocarcinoma

NCT04920032

Q2 2027

Phase 2Recruiting

Colorectal Cancer

NCT05343013

Phase 1Recruiting

Advanced or Metastatic Solid Tumor

NCT04999761

Q4 2027

Phase 3Not yet recruiting

Colorectal Cancer

NCT07730489

Q4 2028

Phase 2Not yet recruiting

Radiotherapy

NCT07116577

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer9 trials

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

Terminated·GGeorgetown University·Phase 2·NCT02654639·4 enrolled

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Approved for marketing· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.··NCT02286492

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 3·NCT01607957·800 enrolled

Show 6 more trials

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05266820·120 enrolled

Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia

Completed· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 3·NCT01955837·406 enrolled

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 3·NCT03520946·430 enrolled

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Completed·AAIO-Studien-gGmbH·Phase 1·NCT03305913·12 enrolled

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01896856·118 enrolled

A Phase 2, Randomized, Open Label Study to Evaluate Efficacy, Safety, and Tolerability of CA102N Combined With Trifluridine/Tipiracil (TAS-102) Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer (mCRC) Who Failed the Standard Treatment

Suspended·HHoly Stone Healthcare Co., Ltd·Phase 2·NCT06039202·100 enrolled

Colorectal Cancer8 trials

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT05600309·94 enrolled

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT05064059·441 enrolled

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Completed·MMassachusetts General Hospital·Phase 1/2·NCT03223779·52 enrolled

Show 5 more trials

Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04683965·27 enrolled

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT03974594·64 enrolled

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05314101·25 enrolled

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05343013·25 enrolled

A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07730489·130 enrolled

Patients With Advanced Solid Tumors3 trials

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT01867879·44 enrolled

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT02301117·43 enrolled

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT02301104·24 enrolled

Pancreatic Adenocarcinoma2 trials

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Completed·TThe University of Hong Kong·Phase 2·NCT04923529·28 enrolled

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

Terminated·UUniversity of Florida·Phase 2·NCT02921737·7 enrolled

Radiotherapy2 trials

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Not yet recruiting·—·Phase 2·NCT07116577·37 enrolled

TAS-102 Plus Radiotherapy in Elderly ESCC

Not yet recruiting·QQianfoshan Hospital·Phase 1/2·NCT07196345·45 enrolled

22 more indications

mCRC2 trials

Sym004 Versus TAS-102 in Patients With mCRC

Withdrawn·SSymphogen A/S·Phase 3·NCT03717038

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT04868773·12 enrolled

Gastric Cancer2 trials

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 3·NCT02500043·507 enrolled

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06346392·594 enrolled

Adenocarcinoma2 trials

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03686488·23 enrolled

iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Completed·AAHS Cancer Control Alberta·Phase 2·NCT04808791·7 enrolled

Colorectal Carcinoma1 trial

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Unknown status·AAmsterdam UMC, location VUmc·Phase 2/3·NCT03909724·60 enrolled

Colon Adenocarcinoma1 trial

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Recruiting·UUniversity of California, Irvine·Phase 1·NCT04920032·22 enrolled

Tics1 trial

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT01867866·44 enrolled

Bladder Cancer1 trial

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Unknown status·RRahul Parikh·Phase 2·NCT03762161·22 enrolled

Squamous Cell Lung Carcinoma1 trial

TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

Completed·UUniversity of Florida·Phase 2·NCT02920476·4 enrolled

Gastrointestinal Tumors1 trial

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT01916447·65 enrolled

Nasopharyngeal Carcinoma1 trial

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT04627961·33 enrolled

Temozolomide1 trial

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT02943733·18 enrolled

Rectal Cancer1 trial

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

Completed·PProvidence Health & Services·Phase 2·NCT04417699·13 enrolled

Small Cell Lung Cancer1 trial

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Terminated· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2·NCT01904253·18 enrolled

Anlotinib1 trial

TAS-102 and Anlotinib in ≥3 Lines mGC

Unknown status·ZZhejiang University·Phase 2·NCT05029102·45 enrolled

Liver Metastases1 trial

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Completed·UUniversity of California, San Francisco·Phase 1·NCT02602327·21 enrolled

Solid Tumors1 trial

A Phase I Study of TAS-102 in Solid Tumors

Completed· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT02261532·15 enrolled

Pancreatic Cancer1 trial

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Completed·SSun Yat-sen University·Phase 2·NCT05481463·22 enrolled

Gastric Adenocarcinoma1 trial

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·N/A·NCT04517747·20 enrolled

Esophageal Adenocarcinoma1 trial

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Completed·UUniversity of California, Irvine·Phase 1·NCT04074343·20 enrolled

Nivolumab1 trial

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2·NCT02860546·18 enrolled

Colorectal Neoplasms1 trial

A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05328908·769 enrolled

Advanced or Metastatic Solid Tumor1 trial

Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors

Recruiting· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT04999761·917 enrolled

Sources

References

[1]
ClinicalTrials.gov — 49 trial records for TAS 102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAS 102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAS 102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Taiho Oncology, Inc.

TAS 102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Metastatic Colorectal Cancer9 trials

Colorectal Cancer8 trials

Patients With Advanced Solid Tumors3 trials

Pancreatic Adenocarcinoma2 trials

Radiotherapy2 trials

mCRC2 trials

Gastric Cancer2 trials

Adenocarcinoma2 trials

Colorectal Carcinoma1 trial

Colon Adenocarcinoma1 trial

Tics1 trial

Bladder Cancer1 trial

Squamous Cell Lung Carcinoma1 trial

Gastrointestinal Tumors1 trial

Nasopharyngeal Carcinoma1 trial

Temozolomide1 trial

Rectal Cancer1 trial

Small Cell Lung Cancer1 trial

Anlotinib1 trial

Liver Metastases1 trial

Solid Tumors1 trial

Pancreatic Cancer1 trial

Gastric Adenocarcinoma1 trial

Esophageal Adenocarcinoma1 trial

Nivolumab1 trial

Colorectal Neoplasms1 trial

Advanced or Metastatic Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News